For the reduction of thrombotic events in patients with acute coronary syndrome, by Astrazeneca; Approved July 2011
Brilinta (ticagrelor) is a reversibly binding oral adenosine diphosphate (ADP) receptor antagonist. It selectively inhibits P2Y12, a key target receptor for ADP. ADP receptor blockade inhibits the action of platelets in the blood, reducing recurrent thrombotic events.
Brilinta is specifically indicated to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (unstable angina, non-ST elevation myocardial infarction, or ST elevation myocardial infarction).
Brilinta is supplied as a tablet for oral administration. The recommended initial dose is 180 mg (two 90 mg tablets) loading dose and continue treatment with 90 mg twice daily. After the initial loading dose of aspirin (usually 325 mg), use Brilinta with a daily maintenance dose of aspirin of 75-100 mg.
Adverse events associated with the use of Brilinta may include, but are not limited to, the following:
Mechanism of Action
Brilinta (ticagrelor) is a cyclopentyltriazolopyrimidine and inhibits platelet activation and aggregation mediated by the P2Y12 ADP-receptor